Biomarker for Rapid Diagnosis of Hemispheric Stroke

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00916864

Acronym

BE FAST!

Enrollment

250

Registered

2009-06-10

Start date

2009-06-30

Completion date

2011-06-30

Last updated

2011-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Stroke

Brief summary

The aim of the study is to estimate the diagnostic accuracy of a combined biomarker test (including NMDA-Receptor fragments \[NR2-peptide\] and Glial fibrillary acidic protein) used to differentiate between cerebral ischemia and intracerebral hemorrhage in patients with acute hemispheric stroke.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* hemiparesis * at least one sign of cortical involvement (e.g., aphasia, neglect, gaze deviation, reduced level of consciousness) * hospital admission within 4.5 hours after symptom onset

Exclusion criteria

* stroke/TIA within the last 3 months * traumatic brain injury within the last 3 months * history of brain tumor

Design outcomes

Primary

Measure	Time frame
Diagnostic accuracy (sensitivity and specificity for diagnosing cerebral ischemia and intracerebral hemorrhage)	9 months

Countries

Germany

Outcome results